patient

Oral Azacitidine Improves, Sustains Health-Related QoL in AML

Treatment with the oral agent showed sustained health-related quality of life compared with placebo in patients with

Significant Racial, Ethnic Related Socioeconomic Disparities Influence Survival in AML

Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with

Update on Miss Alayna!

Person's Name:

Alayna, daughter of Ashley

Alayna was a toddler when she was diagnosed with severe

Bone Marrow Disease(s):

Content source:

web exclusive

PNH - Traveling with a Rare Disease - Update from Josh

Person's Name:

Joshua Maliczowski

Traveling with a rare disease

Bone Marrow Disease(s):

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Content source:

web exclusive

Beat AML Master Clinical Trial Showcases Paradigm Shift With Precision Medicine

Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with

Crovalimab

An experimental complement inhibitor C5 monoclonal antibody.

Guang-Shing Cheng, M.D.

Cheng, Guang-Shing

Associate Professor

Fred Hutchinson Cancer Research Center

Dr. Guang-Shing Cheng is Associate Professor in the

Online Profile:

Associate Professor

Staci Arnold, MD, MBA, MPH

Arnold, Staci

Assistant Professor of Pediatrics

Children's Healthcare of Atlanta

Dr. Arnold is an Assistant Professor of Pediatrics, Emory University School of Medicine. She specializes in pediatric hematology and has particular expertise in the care of children undergoing stem cell transplantation for noncancerous disorders, such as sickle cell

Online Profile:

Assistant Professor of Pediatrics

Treatment Approaches in AML: Key Testing for Personalized Care

VIDEO

Description:

Treatment Approaches in AML: Key Testing for Personalized Care from Patient Empowerment Network on Vimeo.

Talati Highlights “Game-Changing” Potential of Venetoclax/HMA Combos for Elderly AML

Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received venetoclax/HMA combinations in the real-world setting and the next phase of the ongoing research initiative.

Chetasi Talati, MD
Chetasi Talati, MD